source
- Novartis says it will keep seeking sub-$2 billion bolt-on deals worldwide, staying geography-agnosticNovartis CEO Vas Narasimhan told investors on the second‑quarter earnings call that the company will continue to pursue bolt‑on acquisitions below $2 billion and has no plans to overhaul its busine…
- Agios halts development of sickle cell drug tebapivat after mid-stage trial failureAgios announced it will stop developing tebapivat for sickle cell disease after a mid-stage trial did not meet expectations. The drug, a next-generation pyruvate kinase activator related to the ap…